上皮性卵巢癌腹水的体外化学敏感性测定

In vitro chemosensitivity assay of ascites in epithelial ovarian cancer.

作者信息

Xu X, Dai H, Zhao Y, Wang Y, Xu X, Qian Z, Chen X

机构信息

Department of Chemotherapy, Jiangsu Institute of Cancer Research, Nanjing, China.

Medical School of Yangzhou University, Yangzhou, China.

出版信息

Eur J Gynaecol Oncol. 2013;34(6):559-64.

PMID:24601052

Abstract

OBJECTIVE

This study aimed to investigate the predictive value of 3-(4,5-dimethylthiazol-2-yl)-2,5-diphenyltetrazolium bromide (MTT) assay for chemosensitivity test in ascites.

MATERIALS AND METHODS

The relationship of the in vitro sensitivity results and the clinicopathological characteristics, objective response rates (ORRs) of chemotherapy, and time to progression (TTP) were retrospectively analyzed in 120 epithelial ovarian cancer (EOC) patients. The clinical response criterion was based on the Response Evaluation Criteria in Solid Tumors (RECIST) standard. The log-rank test and Kaplan-Meier curve were used to estimate TTP.

RESULTS

MTT assays revealed that tumor cells from ascites of primary and type II EOC were more sensitive to paclitaxel (PTX) and carboplatin (CBDCA) than relapse (p = 0.01 and p < 0.01, respectively) and type I (p = 0.03, p = 0.02, respectively) EOC. p53 positive expression and Ki67 high expression were associated with high PTX (p = 0.01 and p < 0.01, respectively) and CBDCA (p = 0.03 and p < 0.01, respectively) sensitivity. Ki67 weak positive immunostaining was associated with topotecan (p < 0.01), gemcitabine (p < 0.01), and doxorubicin (p < 0.01) resistance. Chemosensitivity to CBDCA/PTX was associated with the ORR ofneo-adjuvant (p = 0.03) and adjuvant (p = 0.02) chemotherapy. The MTT assay results of ascites were consistent with the clinical response (p = 0.04) and TTP (p = 0.04) in patients with platinum-resistant relapse EOC tumors.

CONCLUSIONS

Evaluation of the chemosensitivity of ascites in EOC by MTT can aid the establishment of individualized clinical chemotherapeutic plans for platinum-resistant relapse patients.

摘要

目的

本研究旨在探讨3-(4,5-二甲基噻唑-2-基)-2,5-二苯基四氮唑溴盐（MTT）法对腹水化疗敏感性检测的预测价值。

材料与方法

回顾性分析120例上皮性卵巢癌（EOC）患者的体外药敏结果与临床病理特征、化疗客观缓解率（ORR）及疾病进展时间（TTP）之间的关系。临床反应标准基于实体瘤疗效评价标准（RECIST）。采用对数秩检验和Kaplan-Meier曲线估计TTP。

结果

MTT法显示，原发性和II型EOC腹水肿瘤细胞对紫杉醇（PTX）和卡铂（CBDCA）的敏感性高于复发（分别为p = 0.01和p < 0.01）和I型（分别为p = 0.03，p = 0.02）EOC。p53阳性表达和Ki67高表达与PTX（分别为p = 0.01和p < 0.01）和CBDCA（分别为p = 0.03和p < 0.01）高敏感性相关。Ki67弱阳性免疫染色与拓扑替康（p < 0.01）、吉西他滨（p < 0.01）和阿霉素（p < 0.01）耐药相关。对CBDCA/PTX的化疗敏感性与新辅助化疗（p = 0.03）和辅助化疗（p = 0.02）的ORR相关。铂耐药复发EOC肿瘤患者腹水中MTT检测结果与临床反应（p = 0.04）和TTP（p = 0.04）一致。